
A-Card20 mg
ACME Laboratories Ltd.
Established (FDA-approved) Use Isosorbide Mononitrate is indicated for the prevention of angina pectoris due to coronary artery disease.
Isosorbide Mononitrate is indicated for the prevention of angina pectoris due to coronary artery disease. It is used for long-term prophylaxis of exertional angina and is intended to reduce the frequency of anginal attacks with regular, scheduled dosing.
Isosorbide Mononitrate is not intended to abort an acute anginal attack because its onset of action is too slow for that purpose; a fast-acting sublingual nitrate should be used for acute episodes.
Isosorbide Mononitrate is not approved for acute coronary syndromes, acute myocardial infarction, or acute decompensated heart failure, and should not be relied upon for these indications.
| Formulation | Adult Dose | Notes |
|---|---|---|
| Immediate-release tablet | Initially 5-20 mg twice daily, with the two doses given 7 hours apart (e.g., on waking and 7 hours later); may be titrated to 20 mg twice daily after 2-3 days if needed | Asymmetric schedule maintains a nitrate-free interval to reduce tolerance |
| Extended-release tablet | Initially 30-60 mg once daily in the morning; may be increased at intervals of several days to 120 mg once daily; maximum 240 mg/day (rarely required) | Swallow whole; do not crush, chew, or split |
Safety and efficacy in children have not been established; Isosorbide Mononitrate is not recommended for pediatric use.
No well-established dose adjustment is required for renal impairment. In hepatic impairment, start at the lower end of the dosing range with close monitoring for hypotension, as bioavailability may be increased.
Very common: Headache is very common when starting Isosorbide Mononitrate, particularly at the beginning of therapy; it often diminishes with continued regular use and may respond to a mild analgesic.
Common: Dizziness, lightheadedness, flushing, orthostatic (postural) hypotension, reflex tachycardia, nausea.
Less common/rare: Syncope (fainting), especially after the first few doses or with dose increases; rash; and, rarely with very high doses, methemoglobinemia.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.